67 FR 15 pg. 3168 - Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Indolo[2,1-b]quinazole-6, 12-dione Antimalarial Compounds and Methods of Treating Malaria
Type: NOTICEVolume: 67Number: 15Page: 3168
FR document: [FR Doc. 02-1645 Filed 1-22-02; 8:45 am]
Agency: Defense Department
Sub Agency: Department of the Army
Official PDF Version: PDF Version
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Indolo[2,1-b]quinazole-6, 12-dione Antimalarial Compounds and Methods of Treating Malaria
AGENCY:
U.S. Army Medical Research and Materiel Command, DOD.
ACTION:
Notice.
SUMMARY:
In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. 6,284,772 entitled "Indolo[2,1-b]quinazole-6, 12-dione antimalarial compounds and Methods of Treating Malaria" issued 09/04/01. Foreign rights are also available (PCT/US99/22569). This patent has been assigned to the United States Government as represented by the Secretary of the Army.
ADDRESSES:
Commander, U.S. Army Medical Research and Materiel Command, ATN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues Dr. Paul Mele, Office of Research Technology Assessment, (301) 619-6664. Both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION:
Compounds, compositions and methods are provided for treating malaria parasites in vitro and in vivo by administering indolo [2,1-b]quinazoline-6, 12-dione compounds of Formula 1. On Formula 1 A, B, C, D, E, F, G and H are independently selected from carbon and nitrogen, or A and B or C and D can be taken together to be nitrogen or sulfer, with the proviso that not more than three of A, B, C, D, E, F, G and H are other than carbon; wherein R1 through R8 are independently selected from the group consisting of, but not limited to, the halogens, alkyl groups, trifluoromethyl groups, methoxyl groups, the carboxy methyl or carboxy ethyl group, nitro, aryl, heteroaryl, cyano, amino, dialkylaminoalkyl, 1-(4-alkylpiperazinyl), and the pharmaceutically acceptable salts thereof; and wherein X is independently selected from the group consisting of any atom especially oxygen, or any side chain necessary to make the indolo[2,1-b]quinazoline-6, 12-dione compound a "prodrug" as the term is understood by one of ordinary skill in the art of medicinal chemistry. In other words, a side chain having a structure where a carbon-nitrogen double bond bears substituents that make the prodrug more water soluble and bioavailable.
Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-1645 Filed 1-22-02; 8:45 am]
BILLING CODE 3710-08-M